Apogee doses first healthy volunteers in Phase 1 trial of TSLP antibody APG333

Apogee Therapeutics, Inc.

APG333 is a novel half-life extended monoclonal antibody targeting TSLP for asthma, COPD, and I&I conditions.
Phase 1 trial: double-blind, placebo-controlled, single-ascending dose in ~32 healthy volunteers across 4 cohorts.
Interim safety and pharmacokinetic data expected in second half of 2025.
Preclinical proof-of-concept achieved for APG777+APG333 combination; clinical trial planning underway in asthma and COPD.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.